News
-
-
PRESS RELEASE
GENFIT Highlights Long-Term Commercial Opportunity for its MASH Diagnostics Technology
GENFIT highlights long-term commercial opportunity for its MASH Diagnostics Technology. The technology aims to identify patients with 'at-risk MASH' through non-invasive blood-based testing, creating potential for significant revenue streams -
-
PRESS RELEASE
GENFIT Annual Combined General Meeting of June 15, 2026 — Availability of Preparatory Documents
GENFIT announces availability of preparatory documents for Annual Combined General Meeting on June 15, 2026. Shareholders can access information on the Company's website. Meeting will be broadcasted live and shareholders can vote online via VOTACCESS platform -
-
-
-
-
-
PRESS RELEASE
GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net sales
GENFIT receives US$20M milestone from Ipsen as Iqirvo® surpasses US$200M net sales threshold in 2025. Phase 3 in PSC confirmed. CCA Phase 1b study progressing as planned. Financial position reinforced
